

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 April 2023 (06.04.2023)



(10) International Publication Number
WO 2023/053084 A1

(51) International Patent Classification:

A61K 31/4166 (2006.01) A61K 47/22 (2006.01)
A61K 9/107 (2006.01) A61K 47/44 (2017.01)
A61K 47/14 (2017.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2022/059345

(22) International Filing Date:

30 September 2022 (30.09.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

202111044703 01 October 2021 (01.10.2021) IN

(71) Applicant: **FERRING B.V.** [NL/NL]; Polaris Avenue 144,
2132 JX Hoofddorp (NL).

(72) Inventors: **PADHI, BijayKumar**; Ferring Pharmaceuticals Pvt. Ltd., Ferring Hyderabad Product Development Centre, Plot No. 14, TSIIC Biotech Park, Phase II Extn, Lalgadi Malakpet (V), Shamirpet (M), Medchal – Malkajgiri (Dt), Hyderabad 500 501 (IN). **BIRADAR, Shailesh Vishwanath**; Ferring Pharmaceuticals Pvt. Ltd., Ferring Hyderabad Product Development Centre, Plot No. 14, TSIIC


Biotech Park, Phase II Extn, Lalgadi Malakpet (V), Shamirpet (M), Medchal – Malkajgiri (Dt), Hyderabad 500 501 (IN). **SONGA, Ambedkar Sunil**; Ferring Pharmaceuticals Pvt. Ltd., Ferring Hyderabad Product Development Centre, Plot No. 14, TSIIC Biotech Park, Phase II Extn, Lalgadi Malakpet (V), Shamirpet (M), Medchal – Malkajgiri (Dt), Hyderabad 500 501 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: ORAL LIQUID ENZALUTAMIDE COMPOSITIONS

FIG. 8



(57) Abstract: Described herein are oral liquid pharmaceutical compositions comprising enzalutamide and therapeutic methods for using them.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*